ICAM-1 and CD11b inhibition worsen outcome in rats with E. coli pneumonia

Fabrice Zeni, Chantal Parent, Rosaly Correa, Charles Natanson, Bradley Freeman, Joseph Fontana, Marcello Quezado, Robert L. Danner, Yvonne Fitz, Steve Richmond, Eric Gerstenberger, Steven M. Banks, Peter Q. Eichacker

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


We investigated whether inhibiting an endothelial adhesion molecule [intracellular adhesion molecule 1 (ICAM-1)] would alter outcome and lung injury in a similar fashion to inhibition of a leukocyte adhesion molecule (integrin CD11b) in a rat model of gram-negative pneumonia. Inhibition of ICAM-1 with monoclonal antibody (MAb) 1A29 (1 mg/kg sc or 0.2 or 2 mg/kg iv, q 12 h x 3) or of CD11b with MAb 1B6 (1 mg/kg sc, q 12 h x 3) were compared against similarly administered placebo proteins in rats challenged with intrabronchial Escherichia coli. After challenge, all animals were treated with antibiotics. ICAM-1 MAb (6 mg/kg, iv, total dose) increased mortality vs. control (P = 0.03). CD11b MAb (3 mg/kg, sc, total dose) did not significantly (P = 0.16) increase mortality rates, but this was not in a range of probability to exclude a harmful effect. All other doses of MAb had no significant effect on survival rates. ICAM-1 and CD11b MAbs had significantly different effects on the time course of lung injury, circulating white cells and lymphocytes, and lung lavage white cells and neutrophils (P = 0.04-0.003). CD11b MAb decreased, whereas ICAM-1 MAb increased these measures compared with control from 6 to 12 h after E. coli. However, from 144 to 168 h after E. coli both MAbs increased these measures compared with control rats but to a greater level with CD11b MAb. Thus both ICAM-1 and CD11b appear to be necessary for survival during E. coli pneumonia. Although these adhesion molecules may participate differently in early lung injury, with CD11b increasing and ICAM-1 decreasing inflammation and injury, both are important for the resolution of later injury. During gram-negative pneumonia the protective roles of ICAM-1 and CD11b may make their therapeutic inhibition difficult.

Original languageEnglish
Pages (from-to)299-307
Number of pages9
JournalJournal of Applied Physiology
Issue number1
StatePublished - Jul 1999


  • Acute lung injury
  • Adhesion molecule
  • Neutrophil
  • Pneumonia
  • Sepsis


Dive into the research topics of 'ICAM-1 and CD11b inhibition worsen outcome in rats with E. coli pneumonia'. Together they form a unique fingerprint.

Cite this